Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study)-Reference-Cited by-同舟云学术

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study)

Published:2004-06 Issue:9 Volume:18 Page:1305-1310
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

Breilh Dominique,Pellegrin Isabelle,Rouzés Agnés,Berthoin Karine,Xuereb Fabien,Budzinski Hélène,Munck Michèle,Fleury Hervé JA,Saux Marie-Claude,Pellegrin Jean-Luc

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference18 articles.

1. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)

2. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy

3. Pharmacokinetics and Resistance Mutations Affect Virologic Response to Ritonavir/Saquinavir-Containing Regimens

4. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

5. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a method for the quantitative determination of ritonavir and lopinavir in blood plasma;Ural Medical Journal;2023-12-22

2. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis;Drug Metabolism and Pharmacokinetics;2022-12

3. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients;Therapeutic Drug Monitoring;2021-02

4. Development and validation of a cost‐effective and sensitive bioanalytical HPLC‐UV method for determination of lopinavir in rat and human plasma;Biomedical Chromatography;2020-07-10

5. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week;Annals of Clinical Microbiology and Antimicrobials;2020-01-22